GREATER CANNABIS CO INC - GCAN STOCK NEWS

Greater Cannabis Company (GCAN) has submitted a clinical trial application to the Israel Ministry of Health for a Phase 2 trial of its cannabinoid therapy targeting autism spectrum disorders (ASD) and other neuropsychiatric illnesses. The double-blind trial will involve 100 patients aged 4-17, aiming to assess safety and efficacy. Expected to enroll participants in the first half of 2023, this study may lead to a treatment option for ASD and similar disorders, addressing a significant unmet medical need.

Greater Cannabis Company (OTC: GCAN) announced that Dr. Adi Aran will be featured on CNN in the documentary WEED 6: Cannabis and Autism, airing on December 19 at 9 PM ET. Dr. Aran, a leader in cannabinoid research, will discuss the therapeutic effects of cannabinoids in treating autism. This installment follows Dr. Sanjay Gupta's exploration of medical marijuana's benefits, focusing on its impact on children with autism. The special will be available on various streaming platforms, enhancing visibility for GCAN's cannabinoid therapeutics.

The Greater Cannabis Company (OTC: GCAN) has appointed Dr. Adi Aran, a leading pediatric neurologist, to advance its cannabinoid therapeutic pipeline. Dr. Aran, known for his research in cannabinoid treatments for autism, will spearhead product development and clinical studies. His experience in cannabinoid therapies is expected to enhance GCAN's strategic objectives and innovation in treatment options. According to CEO Aitan Zacharin, Dr. Aran's expertise will significantly contribute to the company's mission of providing effective medical solutions for unmet patient needs.

Greater Cannabis Company (OTC: GCAN) announced the initiation of a preclinical study for its neuropsychiatric cannabinoid therapy. This follows a license and research agreement with Shaare Zedek Scientific, led by Dr. Adi Aran. The study aims to evaluate the synergistic effects of the therapeutic in a preclinical model and is expected to conclude by Q3 2022, with interim evaluations starting Q1 2022. CEO Aitan Zacharin highlighted the unmet need in treating neuropsychiatric disorders, expressing confidence in the therapy's efficacy compared to traditional treatments.

Greater Cannabis Company (GCAN) has entered a licensing agreement with Shaare Zedek Scientific Ltd. for a novel cannabinoid therapy aimed at treating autism, schizophrenia, and other neuropsychiatric disorders. This partnership includes a joint research development initiative led by Dr. Adi Aran from Shaare Zedek Medical Center, known for its extensive clinical research. Dr. Aran’s previous studies demonstrated significant improvements in behavioral issues for autistic children using cannabis-based therapies.

The Greater Cannabis Company (OTCQB: GCAN) has announced a collaboration with Israel's Phytor LTD to develop cannabinoid and botanical-based therapeutics targeting dermatological and chronic ailments. Led by Dr. Yehoshua Maor, Phytor is recognized for its expertise in plant-based therapeutics. This partnership aims to create more effective, natural solutions that can provide rapid relief compared to conventional treatments. Both companies will integrate their technologies to enhance product offerings for consumer and commercial use.

The Greater Cannabis Company (OTCQB: GCAN) announced the reinstatement of its common stock for trading on the OTCQB Venture Market after a compliance review. This upgrade reflects adherence to high financial standards and improved corporate governance, which the Company believes will enhance investor benefits.

The move is expected to increase transparency, reporting standards, and liquidity, as the OTCQB is viewed as an established public market by the SEC. This tier is known to improve awareness and analyst coverage for companies.